Precision BioSciences Announces Allowance of Second U.S. Patent for Engineered Meganucleases
1/25/2012 6:28:49 AM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office (PTO) has issued a Notice of Allowance for U.S. Patent Application 13/245,596 (“the '596 Application”). The allowed claims relate to a class of engineered meganucleases containing specific mutations that impact affinity for DNA. These mutations are important for the successful use of meganucleases as genome engineering tools and are used widely as a part of Precision’s DNE genome engineering technology. The allowance of the claims of the '596 Application augments Precision’s ability to defend its DNE technology, aspects of which are already protected under Precision’s U.S. Patent No. 8,021,867 (“the '867 Patent”). Precision announced in October 2011 that it has asserted the '867 Patent against Cellectis SA in a suit pending in the U.S. District Court for the Eastern District of North Carolina.